Phase 2 Active Treatment Study to Evaluate the Efficacy and Safety of SRK-015 in Patients With Later-Onset Spinal Muscular Atrophy (TOPAZ)
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs SRK-015 (Primary)
- Indications Spinal muscular atrophy
- Focus Proof of concept; Therapeutic Use
- Acronyms TOPAZ
- Sponsors Scholar Rock
- 19 Nov 2019 According to an Scholar Rock Media release, the interim results are expected in the first half of 2020 with top-line results for the full 12-month treatment period expected starting in the fourth quarter of 2020 and through the first quarter of 2021.
- 19 Nov 2019 Results (n=29) presented in a Scholar Rock Media release.
- 03 Jun 2019 According to an Scholar Rock Media release, data from an earlier Phase 1 trial of SRK-015 in healthy volunteers will support the evaluation for this trial.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History